AFT Pharmaceuticals faces change in CFO succession plan

An update from AFT Pharmaceuticals Ltd. ( (AU:AFP) ) is now available.

AFT Pharmaceuticals, New Zealand’s largest domestic pharmaceuticals company, has announced that Chief Financial Officer-designate Simon Bosley will not assume the CFO role for personal reasons. He will nonetheless remain with the business until the end of July to assist during the transition as the company recruits a successor.

The new appointee will replace long-serving CFO Malcolm Tubby, who is scheduled to retire at the end of May 2026, marking a significant leadership change in AFT’s finance function. Managing director Dr Hartley Atkinson acknowledged Bosley’s contribution and support through the transition, underscoring the company’s focus on maintaining continuity in its financial leadership during this period of executive turnover.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals is a New Zealand-based multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of proprietary and in-licensed medicines. Its products span multiple therapeutic categories and are sold through over-the-counter, prescription, and hospital channels across core markets including Australia, New Zealand, Asia, North America, and Europe, with out-licensing to partners in more than 125 countries worldwide.

For an in-depth examination of AFP stock, go to TipRanks’ Overview page.